NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Thursday that its fourth quarter revenues rose 15 percent year over year thanks largely to an uptick in testing revenues.

For the three months ended Dec. 31, the diagnostics company said Q4 2017 revenues rose to $12.5 million from $10.9 million in Q4 2016, beating analysts' average estimate of $12.3 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.